Medical device startup nContact Surgical is planning to grow its business with new hires, additional productions and ongoing support of three clinical trials now that it has closed on $16 million in new financing.

nContact is focused on technology to “develop and investigate medical devices for the minimally invasive treatment of heart arrhythmias.” The company is working with surgeons and interventional physicians on the technology.

Since launch in 2005, nContact has raised $42.4 million in financing through four rounds.

A new investor, ZMV Associates, joined the round which was led by existing investor Harbert Venture Partners.

nContact manufactures a device that is already approved by the Food and Drug Administration for endoscopic cardiac coagulation.

Clinical trials are underway for use of the device in other procedures.

“This new round of funding will further strengthen nContact’s leadership position in developing technologies with the capability to access the heart and treat cardiac arrhythmias with a ‘subtle’ (sub-thoracic total endoscopic) procedure,” said Chief Executive Officer John Funkhouser in a statement.

“nContact’s current technology has enabled physicians to develop the Convergent Procedure, which brings together the best techniques of the cardiac surgeon and electrophysiologist into a single, comprehensive procedure that may provide an effective, completely closed chest treatment option for even the most difficult to treat AF [atrial fibrillation] patients,” he added.

The company also recently received a $244,479 federal grant as part of the Patient Protection and Affordable Care Act for a “Qualifying Therapeutic Discovery Project.”

Get the latest news alerts: Follow LTW at Twitter.